Assessing and improving the quality of guideline-adherent hepatitis B virus care in people with HIV: A cross-sectional study
International Journal of STD & AIDS · 2024
DOI: 10.1177/09564624231203735 ↗Kurz gefasst
Leitlinie in der Zeitschrift International Journal of STD & AIDS, 2024. Verfasst von Patrick Ga Oomen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, University Medical Centre Utrecht, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: HIV Infections, Coinfection, Hepatitis B, Guideline Adherence. Die Arbeit nennt 16 Literaturangaben.
Abstract (Originalsprache)
The increasing use of non-tenofovir containing antiretroviral regimens calls for renewed attention to the prevention and management of hepatitis B virus (HBV) in people with HIV (PWH). We retrospectively assessed adherence to HBV guidelines, including complete HBV screening in PWH. In people with HIV/HBV co-infection, this included HBV therapy, screening for hepatitis delta virus (HDV) and on-therapy virologic response monitoring. HIV/HBV co-infection in PWH was defined as the presence of hepatitis B surface antigen (HBsAg) at the last measurement before study entry or detectable HBV-DNA for ≥6 months. After assessment, missing laboratory tests were performed to optimize HBV monitoring and screening for co-infections. Of all PWH under follow-up, 1484/1633 (90.9%) were adequately screened for HBV. After performing missing screening tests, 466 of 1618 PWH with complete screening results (28.8%) were non-immune for HBV infection. Fifty-one (3.2%) with HIV/HBV co-infection were identified. HBV treatment was adequate in 51/51 (100%). Screening for hepatitis A, C and delta virus antibodies and fibrosis was performed in 51/51 (100%), 49/51 (96.1%), 17/51 (35.3%) and 38/51 (74.5%). Annual HBV-DNA or HBsAg monitoring was done in 18/51 (35.3%) and hepatocellular carcinoma (HCC) surveillance in 2/9 (22.2%) of those indicated. Additional testing in those with missing data identified 4/34 (11.8%) persons with HDV antibodies and 3/30 (10%) with HBsAg seroclearance. Our study demonstrates the feasibility and added value of evaluating HBV care components and performing missing laboratory tests, identifying a large number of HBV vaccination candidates and HDV antibody screening, HBsAg monitoring and HCC surveillance as key areas for improvement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, University Medical Centre Utrecht, Utrecht, The Netherlands.
- Department of Medical Microbiology, University Medical Centre Utrecht, Utrecht, The Netherlands.
ORCID-Profile: Patrick Ga Oomen, Frans M Verduyn Lunel
Zitieren
APA
Oomen, P. G., van Kraaij, V. J., Gerritsma, A. M., Verduyn Lunel, F. M., Boland, G. J., Hoepelman, A. I., & van Welzen, B. J. (2024). Assessing and improving the quality of guideline-adherent hepatitis B virus care in people with HIV: A cross-sectional study. International Journal of STD & AIDS. https://doi.org/10.1177/09564624231203735
Vancouver
Oomen PG, van Kraaij VJ, Gerritsma AM, Verduyn Lunel FM, Boland GJ, Hoepelman AI, et al. Assessing and improving the quality of guideline-adherent hepatitis B virus care in people with HIV: A cross-sectional study. International Journal of STD & AIDS. 2024. doi:10.1177/09564624231203735
BibTeX
@article{Oomen2024,
author = {Oomen, Patrick Ga and van Kraaij, Vincent Jp and Gerritsma, Anna M and Verduyn Lunel, Frans M and Boland, Greet J and Hoepelman, Andy Im and van Welzen, Berend J},
title = {Assessing and improving the quality of guideline-adherent hepatitis B virus care in people with HIV: A cross-sectional study},
journal = {International Journal of STD & AIDS},
year = {2024},
doi = {10.1177/09564624231203735}
}
EUVIMED